M James Barrett Acquires 1,000,000 Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) Stock
Mersana Therapeutics Inc (NASDAQ:MRSN) major shareholder M James Barrett acquired 1,000,000 shares of the stock in a transaction dated Monday, July 3rd. The shares were purchased at an average cost of $15.00 per share, with a total value of $15,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Mersana Therapeutics Inc (MRSN) traded down 4.57% during trading on Thursday, hitting $13.35. 146,968 shares of the company traded hands. Mersana Therapeutics Inc has a 52 week low of $12.71 and a 52 week high of $14.70. The stock’s market cap is $302.32 million.
ILLEGAL ACTIVITY NOTICE: “M James Barrett Acquires 1,000,000 Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/06/m-james-barrett-acquires-1000000-shares-of-mersana-therapeutics-inc-nasdaqmrsn-stock.html.
About Mersana Therapeutics
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.